Immunotherapy of malignant non-Hodgkin's lymphomas

被引：0

作者：

Heß G. ^{[1
,2
]}

机构：

[1] III. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität Mainz

[2] III. Medizinische Klinik und Poliklinik, Johannes Gutenberg-Universität, 55101 Mainz

来源：

Der Onkologe | 2005年 / 11卷 / 5期

关键词：

Malignant lymphoma; Monoclonal antibody; Radioimmuntherapy; Vaccination;

D O I：

10.1007/s00761-005-0869-6

中图分类号：

学科分类号：

摘要：

Even if improvements in conventional or dose-escalated chemotherapeutic approaches have positively influenced the results of treatment of indolent or aggressive non-Hodgkin's lymphoma (NHL), most of the patients with malignant lymphoma ultimately die of their disease. In addition to traditional treatment tools, immunotherapeutic approaches now have been widely accepted as part of standard therapies of indolent and aggressive NHL. Mainly monoclonal antibodies for passive immunotherapy have become well established. However, studies investigating active immunization are under way using various approaches. Most recently, allogeneic transplantation has become more attractive, especially for high-risk patients. © Springer Medizin Verlag 2005.

引用

页码：571 / 577

页数：6

共 39 条

[1]

Bendandi M., Gocke C.D., Kobrin C.B., Et al., Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma, Nat Med, 10, pp. 1171-1177, (1999)

[2]

Coiffier B., Haioun C., Ketterer N., Et al., Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: Multicenter phase II study, Blood, 92, pp. 1927-1932, (1998)

[3]

Coiffier B., Feugier P., Sebban C., Et al., Long term results of the GELA study, R-CHOP vs. CHOP in elderly patients with diffuse large B-cell-Lymphoma, Blood, 103, (2004)

[4]

Coiffier B., Lepage E., Briere J., Et al., CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma, N Engl J Med, 346, pp. 235-242, (2002)

[5]

Czuczman M.S., Grillo-Lopez A.J., White C.A., Et al., Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti CD20 monoclonal antibody and CHOP chemotherapy, J Clin Oncol, 17, pp. 268-276, (1999)

[6]

Czuczman M.S., Weaver R., Alkuzweny B., Et al., Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up, J Clin Oncol, 22, pp. 4659-4664, (2004)

[7]

Davis T.A., Maloney D.G., Czerwinski D.K., Et al., Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's Lymphoma without eradicating the malignant clone, Blood, 92, pp. 1185-1190, (1998)

[8]

Ehrlich P., Über den jetzigen Stand der Karzinomforschung, The Collected Papers of Paul Ehrlich, 2, pp. 550-557, (1957)

[9]

Lenz G., Dreyling M., Hoster E., Et al., Immunochemotherapy with Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG), Journal of Clinical Oncology, 23, pp. 1984-1992, (2005)

[10]

Fisher R.I., Dana B.W., Leblanc M., Et al., Interferon alpha consolidation after intensive chemotherapy does not prolong the progression-free survival of patients with low-grade non-Hodgkin's lymphoma: Results of the Southwest Oncology Group randomized phase III study 8809, J Clin Oncol, 18, pp. 2010-2016, (2000)

← 1 2 3 4 →